Not all of the dangerous, controversial drugs are banned in baseball

64 Comments

We get up in arms about testosterone and HGH — substances our bodies naturally produce and which have few serious side effects or long-lasting consequences — because they’re on a banned list. Meanwhile there’s a drug that a lot of athletes take under the direction and supervision of their teams which can kill people and is banned in several countries: the anti-inflammatory Toradol.

Gordon Edes of ESPN Boston has a story about its use in baseball. The hook: an interview with Jonathan Papelbon who took it routinely when he was with the Red Sox but who was told by the Phillies that he can no longer take it as they do not allow it.  Edes looks into the controversial drug, notes its serious side effects, which can include internal bleeding (Clay Buchholz believes it’s what led to him contracting esophagitis which landed him in the ICU) and notes that it’s banned in several countries, for athletes and normal folks alike.

Papelbon’s description of its use in Major League Baseball is pretty familiar-sounding: it’s taken before the game to help guys “get through a 162 game season.” It’s, by definition, a performance enhancing drug. It’s letting guys do things they otherwise couldn’t do. Allowing their bodies to recover faster which allows them to train harder and compete at a more intense level than they otherwise could. Except it’s not on a banned list so no one cares despite the fact that it has the potential to kill you.

There is a tremendous disconnect between the drugs people think are awful in sports and the drugs that truly have the potential to be harmful. This is maybe the best example. Might be nice if we thought about our priorities about these things once in a while.

Royals sign Michael Saunders to a minor-league deal

Getty Images
Leave a comment

Free agent outfielder Michael Saunders has agreed to a minor-league contract with the Royals, the team announced Friday. While the move comes just two days after Saunders agreed to terms with the Pirates, he allegedly asked for his release after the club acquired outfielder Corey Dickerson in a multi-player swap with the Rays on Thursday. MLB.com’s Jeffrey Flanagan adds that Saunders will make $1.5 million upon reaching the majors, with a potential $500,000 in bonuses.

After earning his first spot on an All-Star team in 2016, Saunders followed up a solid campaign with a career-worst performance in 2017. The 31-year-old split the season between the Phillies and Blue Jays’ camps, batting a combined .202/.256/.344 with six home runs and -0.7 fWAR in 234 plate appearances. Although he remained healthy throughout the year, with no sign of the lingering hamstring strain that has plagued him on and off since 2013, he wasn’t productive enough to merit a full-time role on either roster.

With Dickerson slated for a starting role in Pittsburgh, it was unlikely that Saunders would have commanded anything other than a backup role in 2018. Now, however, he’ll compete for playing time amid a slew of outfield options, including Alex Gordon, Cody Asche, Jorge Bonifacio, Tyler Collins and Paulo Orlando.